Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

ALNYLAM PHARMACEUTICALS, INC.

(ALNY)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/03/2019 12/04/2019 12/05/2019 12/06/2019 12/09/2019 Date
122.37(c) 121.98(c) 124.23(c) 123.76(c) 120.71(c) Last
815 122 763 175 980 080 888 878 533 403 Volume
+3.20% -0.32% +1.84% -0.38% -2.46% Change
More quotes
Financials (USD)
Sales 2019 220 M
EBIT 2019 -895 M
Net income 2019 -862 M
Finance 2019 997 M
Yield 2019 -
Sales 2020 444 M
EBIT 2020 -828 M
Net income 2020 -814 M
Finance 2020 474 M
Yield 2020 -
P/E ratio 2019 -15,3x
P/E ratio 2020 -16,8x
EV / Sales2019 56,8x
EV / Sales2020 29,2x
Capitalization 13 458 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for... 
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
11/26ALNYLAM PHARMACEUTICALS : to Webcast Presentations at Upcoming December Investor..
BU
11/25ALNYLAM PHARMACEUTICALS : Announces 2020 Product and Pipeline Goals and Provides..
AQ
11/22ALNYLAM PHARMACEUTICALS : Announces 2020 Product and Pipeline Goals and Provides..
BU
11/21ALNYLAM PHARMACEUTICALS : Announces New and Enhanced Framework for Value-Based A..
AQ
11/21ALNYLAM PHARMACEUTICALS : Announces Approval of GIVLAARI by the U.S. Food and Dr..
AQ
11/20ALNYLAM PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits ..
AQ
11/20ALNYLAM PHARMACEUTICALS : Announces New and Enhanced Framework for Value-Based A..
BU
11/20ALNYLAM PHARMACEUTICALS : Announces Approval of GIVLAARI™ (givosiran) by t..
BU
11/19ALNYLAM PHARMACEUTICALS : Announces Second Annual Advocacy for Impact Grants Pro..
BU
11/12ALNYLAM PHARMACEUTICALS : to Webcast Presentation at Stifel 2019 Healthcare Conf..
BU
11/11ALNYLAM PHARMACEUTICALS : Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for ..
AQ
11/09ALNYLAM PHARMACEUTICALS : Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for ..
BU
10/31ALNYLAM PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
AQ
10/31ALNYLAM : 3Q Earnings Snapshot
AQ
10/31ALNYLAM PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, F..
AQ
More news
News in other languages on ALNYLAM PHARMACEUTICALS, I
07/30ALNYLAM PHARMACEUTICALS : und GENESIS Pharma kooperieren bei der Vermarktung von..
07/30ALNYLAM PHARMACEUTICALS : et GENESIS Pharma entrent en partenariat pour commerci..
05/03EN DIRECT DES MARCHES : Société Générale, Air France, Sanofi, Amazon, Tesla, ..
05/03STOCK MARKET PARIS : "Sell in May", vraiment ?
04/08EN DIRECT DES MARCHES : Renault, Engie, Sanofi, Euronext, Air France KLM, BMW..
More news
Analyst Recommendations on ALNYLAM PHARMACEUTICALS, I
More recommendations
Sector news : Biotechnology & Medical Research - NEC
12/09Sanofi ends research in diabetes, narrows units to spur profit
RE
12/09GILEAD SCIENCES : Says Findings Positive From Real-World Use of Yescarta in Lymp..
DJ
12/06Glencore Faces U.K. Bribery Probe -- WSJ
DJ
12/05REGENERON PHARMACEUTICALS : Reports Positive Phase 2 Data for Pozelimab in PNH
DJ
12/04Glencore to Change 'Old Guard' Ahead Of CEO Transition -- WSJ
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart ALNYLAM PHARMACEUTICALS, INC.
Duration : Period :
Alnylam Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEUTICALS, I
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 123,95  $
Last Close Price 120,71  $
Spread / Highest target 31,7%
Spread / Average Target 2,69%
Spread / Lowest Target -48,6%
EPS Revisions
Managers
NameTitle
John M. Maraganore Chief Executive Officer & Director
Barry E. Greene President
Michael W. Bonney Chairman
Yvonne L. Greenstreet Chief Operating Officer & Executive Vice President
Jeffrey Poulton Chief Financial & Accounting Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICALS, INC.65.56%13 458
IQVIA HOLDINGS INC.26.02%28 407
LONZA GROUP32.31%25 332
INCYTE CORPORATION49.06%20 418
SEATTLE GENETICS, INC.101.43%19 560
CELLTRION, INC.--.--%18 028